Alnylam Pharmaceuticals, Inc.ALNYNASDAQ
Loading
EV to Sales: Discounted ValuationCompressed
Percentile Rank21
3Y CAGR-21.1%
5Y CAGR-14.4%
Year-over-Year Change
Enterprise value to sales ratio
3Y CAGR
-21.1%/yr
vs -25.7%/yr prior
5Y CAGR
-14.4%/yr
Recent deceleration
Acceleration
+4.6pp
Accelerating
Percentile
P21
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
1 yr
Consecutive declineCompressed
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 13.92 | -1.6% |
| 2024 | 14.15 | +6.0% |
| 2023 | 13.35 | -52.9% |
| 2022 | 28.31 | +18.0% |
| 2021 | 24.00 | -21.0% |
| 2020 | 30.37 | -45.9% |
| 2019 | 56.16 | -39.4% |
| 2018 | 92.70 | -23.5% |
| 2017 | 121.11 | +80.7% |
| 2016 | 67.03 | - |